Frederick J. Raal ESC 2021 Inclisiran in polyvascular disease
Steve Nicholls Huygens: Does PCSK9 inhibition impact the vulnerable plaque?
John Chapman LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Chris Packard Why should clinical practice move to an intensive LDL-C lowering approach?
« Back to videos